Interactions of Histone Deacetylase 6 with DNA Damage Repair Factors Strengthen its Utility as a Combination Drug Target in High-Grade Serous Ovarian Cancer Authors: Jolene M. Duda, Stefani N. Thomas Published: 2023 ABSTRACT High-grade serous ovarian cancer (HGSOC) is the deadliest gynecologic malignancy in women. The low survival rate is largely due to drug resistance. Approximately 80% of patients who initially respond to treatment relapse and become drug-resistant. The lack of effective second-line therapeutics remains a substantial challenge for BRCA-1/2 wild-type HGSOC patients. Histone Deacetylases (HDACs) are promising targets in HGSOC treatment; however, the mechanism and efficacy of HDAC inhibitors are understudied in HGSOC. In order to consider HDACs as a treatment target, an improved understanding of their function within HGSOC is required. This includes elucidating HDAC6-specific protein–protein interactions. In this study, we carried out substrate trapping followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) to elucidate HDAC6 catalytic domain (CD)-specific interactors in the context of BRCA-1/2 wild-type HGSOC. Overall, this study identified new HDAC6 substrates that may be unique to HGSOC. The HDAC6-CD1 mutant condition contained the largest number of significant proteins compared to the CD2 mutant and the CD1/2 mutant conditions, suggesting the HDAC6-CD1 domain has catalytic activity that is independent of CD2. Among the identified substrates were proteins involved in DNA damage repair including PARP proteins. These findings further justify the use of HDAC inhibitors as a combination treatment with platinum chemotherapy agents and PARP inhibitors in HGSOC. High-grade serous ovarian cancer (HGSOC) is the deadliest gynecologic malignancy in women1 with a five-year survival rate of <50%. This is largely due to late detection, disease relapse, and drug resistance.2,3 Approximately 80% of patients who initially respond to treatment will relapse and become drug-resistant.4 The primary standard of care for HGSOC patients includes primary debulking surgery followed by chemotherapy.5 There are limited targeted treatments approved for use in HGSOC including poly(ADP-ribose) polymerase inhibitors (PARPi) (Olaparib, Niraparib, Rucaparib) and the vascular endothelial growth factor (VEGF) inhibitor, Bevacizumab. Bevacizumab was initially approved for first-line use in combination with chemotherapy and maintenance therapy.6 PARPi were initially approved for maintenance therapy in patients with advanced epithelial ovarian cancer and homologous recombination (HR) deficient tumors who have had a complete or partial response to first-line chemotherapy.7 PARP proteins bind at sites of single-stranded DNA breaks and recruit DNA damage repair factors through PARylation signaling. PARPi treatment of HR-deficient cells is cytotoxic and causes lethal genomic instability via a phenomenon termed synthetic lethality. PARPi prevent PARP proteins from repairing single-strand DNA breaks, which results in the formation of double-strand DNA breaks. Two major pathways exist for the repair of double-strand DNA breaks: HR and nonhomologous end joining (NHEJ). HR is a high-fidelity DNA damage repair pathway that occurs in the G2/S phase of the cell cycle. HR-deficient cells utilize NHEJ, which typically occurs in the G1 phase and occurs at a faster rate than HR. However, NHEJ is error-prone.8−11 Although PARPi are approved for use as a monotherapy, the development of PARPi resistance remains a significant challenge for HGOSC patients. This has led to the development of PARPi combination therapies. HR status has been used to stratify patients for treatment with PARPi and immune checkpoint inhibitors. Evidence that HR deficiency can result in a higher neoantigen load, likely due to HR defects, has led to the assessment of the combination of PARPi with immune checkpoint inhibitors; however, this treatment approach is in the preclinical testing phase.12 The FDA-approved intended uses for Bevacizumab and Olaparib have been extended to include their use in combination with each other as a first-line therapy.6 However, the use of these targeted inhibitors only extends progression-free survival by an average of 6–18 months.6,13 When disease recurrence occurs, there is a lack of alternative treatments to pursue, and this absence of alternative therapeutic options remains a significant challenge, especially in the setting of HR proficiency. This led to the investigation of alternative drug targets, including histone deacetylases (HDACs). HDACs are a group of enzymes that modulate gene expression through the removal of acetyl functional groups from lysine amino acid residues on histone and nonhistone proteins. There are 18 different HDACs that are divided into four classes: I, II, III, and IV. The different classes are distinguished by localization and sequence homology.14,15 HDAC6, a class IIb HDAC, is the largest member of the HDAC family based on the number of amino acids. HDAC6 has a significant role in many cellular processes and, specifically, in cancer-related pathways. These pathways and processes include cell motility, stress response, autophagy, apoptosis, proliferation, and migration.16−20 Previous studies have associated increased HDAC6 expression levels with poor prognosis and chemotherapy resistance in HGSOC,15,18 making HDAC6 a promising target for cancer treatment. HDAC6 is a primarily cytoplasmic enzyme15,21 that contains an internal duplication of two catalytic domains (CD). The two domains are believed to have separate substrate targets.22−24 Previous studies have shown that the CD1 and CD2 domains both contain deacetylase activity,25,26 while others have claimed that only CD2 is catalytically active.27 The contradictory functionality between CD1 and CD2 domains may be due to differing methods of analysis, such as the use of recombinant purified proteins versus cell lysates or the variable utility of the opposing domains across cell types. Nevertheless, the exact functional roles of CD1 and CD2 are not well-established. The function of HDACs and their role in cancer progression and development have led to the development and implementation of HDAC inhibitors (HDACi). However, HDACi has yet to gain FDA approval for intended uses related to HGSOC treatment. There is still much unknown regarding the role of HDACi and, specifically, their function in HGSOC.29 In order to consider HDACs as a therapeutic target in HGSOC we need to better understand their function in HGSOC, including their protein–protein interactions. Applying a catalytically inactive mutant allows substrates to bind to enzymes for a longer period of time and enables the detection of interacting proteins, including transient interactors, using immunoprecipitation coupled with mass spectrometry analysis, as described previously.28−31 Mass spectrometry-basedanalysis can facilitate a comprehensive understanding of the HGSOC proteome, thereby enabling the elucidation of functional consequences of genomic changes.32 This analytical approach can also enable the identification of new therapeutic vulnerabilities to decrease drug resistance. In this study, we carried out the method of substrate trapping to identify novel HDAC6 interactors in the context of HR-proficient HGSOC using catalytically inactive mutants of HDAC6 having mutations in either CD1 (H216A), CD2 (H611A), or CD1 and CD2 (CD1/2) (H216A/H611A). We found that the CD1 and CD2 domains had unique substrates, suggesting that both domains are catalytically active. HDAC6 interactions also overlapped between the two domains. DNA damage repair factors and PARP proteins were among the HDAC6-interacting proteins identified using both of the catalytically inactive mutants, which provides justification for combination treatments of HDAC inhibitors with PARP inhibitors in HGSOC. Materials and Methods HDAC6 Mutant Plasmid Generation and Transfection HDAC6-mutant plasmids were generated by Genscript using an HDAC6 OHu63602D plasmid construct and the pcDNA3.1+/C-(K)-DYK cloning vector using CloneEZ. Genscript also carried out site-directed mutagenesis of the HDAC6 plasmid construct to obtain plasmids with the following point mutations in the overall protein structure: H216A, H611A, and H216A/H611A. The point mutations of the ORF clone of each plasmid were as follows: H230A, H625A, H230A/H625A. OVCAR3 cells (ATCC) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 20% fetal bovine serum, 0.01 mg/mL bovine insulin, 1% penicillin/streptomycin, and 100 μg/mL normocin and maintained at 37 °C with 5% CO2. Cells were seeded at 70% confluency and allowed to attach for 24 h. The following day, the cells were transfected with either H216A (CD1), H611A (CD2), H216A/H611A (CD1/2), wild-type HDAC6 (WT) plasmids, or a vehicle control using JetOPTIMUS (Polyplus) in serum-free, antibiotic-free media. The JetOPTIMUS protocol was optimized to use 0.5× DNA with a DNA/jetOPTIMUS ratio of 1:1. After 4 h, the reagent-containing media was replaced with serum-containing media for 24 h. The cells were then treated with either 10 μM Vorinostat or DMSO for another 24 h. Immunoprecipitation Immunoprecipitation was adapted from the FLAG Immunoprecipitation Kit protocol for the Anti-FLAG-M2 affinity gel (Millipore Sigma). The transfected cells were washed twice with ice-cold PBS, and then 500 μL of lysis buffer (50 mM Tris HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) was added to each plate and rocked on ice for 30 min. The lysed cells were harvested and centrifuged for 10 min at 12,000g (4 °C). The supernatant was collected, and the pellet was stored at −80 °C. The Anti-FLAG M2 affinity gel suspension was aliquoted to contain 40 μL of suspension (20 μL of packed gel volume) per sample. The resin was washed twice in ice-cold PBS, then 3 times in 1× wash buffer (10× wash buffer: 0.5 M Tris HCl (pH 7.4), 1.5 M NaCl). The resin was centrifuged for 30 s at 5000g (4 °C) after each wash. Then, 750 μg of protein was added to each tube containing the washed resin, and the tube was placed on a rotating rack (end-over end) at 4 °C overnight. The resin was centrifuged for 30 s at 5000g (4 °C), and the unbound supernatant was carefully removed and stored at −80 °C. The resin was washed 3 times with 1× wash buffer and centrifuged for 30 s at 5000g (4 °C) after each wash. Then 30 μL of Bolt 2× LDS sample buffer (Novex) was added to each sample. Samples were boiled at 95 °C for 5 min and centrifuged briefly; then, 5 μL of supernatant was aliquoted from each sample to validate the transfection and immunoprecipitation via Western blot. The remaining supernatant was stored at −80 °C. SDS-PAGE and Western Blot The immunoprecipitation input and eluted samples were reduced with Bolt 10× sample reducing agent (Novex) and boiled at 95 °C for 10 min, then loaded on a Bolt 4–12% Bis-Tris Plus gel (Invitrogen) and run at 200 V for 35 min. The gel was transferred to a nitrocellulose membrane using semidry transfer for 13 min. After the transfer, the nitrocellulose membrane was washed 3 times for 5 min with 1× TBS/0.1% Tween-20 (TBS-T), then stained with Ponceau S for 10 min to ensure protein transfer efficiency. The Ponceau S stain was washed from the membrane using 1× TBS-T, and then the membrane was blocked in 5% nonfat milk in 1× TBS-T for 1 h. The membrane was probed with a rabbit Monorab DYKDDDDK Tag (Genscript) antibody overnight at 4 °C. The membrane was washed 3 times for 10 min with 1× TBS-T then incubated with a goat antirabbit IgG-HRP secondary antibody for 1 h at room temperature, then washed 3 min × 10 min with 1× TBS-T. Chemiluminescence detection was carried out using SuperSignal West Pico Plus (Thermo Scientific) and CL-Xposure Film (Thermo Scientific) (Figure S1). SDS-PAGE and In-Gel Digestion After validating the efficiency of the transfection and immunoprecipitation, the remaining 25 μL of the sample was loaded on a 4–12% Bis-Tris plus gel and run at 200 V for 35 min. The gel was stained using Coomassie blue for 1 h then washed with deionized water for 1 h (Figure S2). Each lane/sample was excised into 6 regions. The excised regions were diced into ∼1 mm3 pieces and placed in 75 μL of 1:1 (Acetonitrile: 100 mM NH4HCO3), vortexed, and incubated at 4 °C overnight. The solution was removed and discarded, followed by 2 washes at room temperature for 15 min. The gel pieces were then dehydrated with 75 μL of 100% acetonitrile for 30 s. The acetonitrile was removed, and the gel pieces were rehydrated with 75 μL of 10 mM DTT and incubated for 1 h at 56 °C. After incubating, the DTT solution was removed, and the gel pieces were washed with 75 μL of 100 mM NH4HCO3 for 5 min. The NH4HCO3 solution was removed, and 75 μL of 55 mM iodoacetamide was added to the gel pieces, followed by incubation for 30 min at room temperature in the dark. The iodoacetamide solution was removed, and the gel pieces were washed with 75 μL of 1:1 100 mM NH4HCO3/acetonitrile for 15 min at room temperature. The solution was removed, and the gel pieces were dehydrated with 100% acetonitrile for 30 s. The gel pieces were rehydrated with 12.5 ng/μL trypsin in 50 mM NH4HCO3 and set on ice for 15 min. The remaining solution was removed and replaced with 70 μL of 50 mM NH4HCO3, and the gel pieces were incubated at 37 °C overnight. The supernatant was recovered in a methanol-rinsed microcentrifuge tube, and 50 mM NH4HCO3 was added to the gel pieces for 15 min at room temperature with shaking (400 rpm). The gel pieces were briefly centrifuged, and the supernatant was added to the methanol-rinsed tubes. Then, 50% acetonitrile: 5% formic acid was added to the gel pieces and incubated for 15 min with shaking (400 rpm) at room temperature. The supernatant was then added to the supernatant from the previous steps, and this step was repeated twice. The pooled extracts were then dried in a speed vac and desalted using C18 STAGE tips. C18 Stop and Go Extraction (STAGE) Tip Desalting C18 STAGE tip desalting was carried out based on the method described by Mertins and Rappsilber.33−35 Briefly, 200 μL C18 STAGE tips were prepared using two Empore C18 extraction disks. The STAGE tips were conditioned with 100 μL of acetonitrile and then centrifuged at 3000g for 3 min at room temperature. The STAGE tips were washed with 100 μL of 50% acetonitrile/0.1% formic acid. This was followed by equilibration twice with 100 μL of 0.1% formic acid. Samples were loaded onto the conditioned STAGE tips and washed twice with 100 μL of 0.1% formic acid. Then, the samples were eluted with 60 μL of 50% acetonitrile/0.1% formic acid and dried using a speed vac. Mass Spectrometry Analysis The peptides were reconstituted in 5% acetonitrile/0.1% formic acid and analyzed on an Orbitrap Q Exactive Plus mass spectrometer (Thermo Fisher Scientific) equipped with an Ultimate 3000 RSLCnano liquid chromatography system. 1/3 of each sample was injected into an EASY-Spray HPLC Column (75 μm x 150 mm, 3 μm C18 particle size) with the spray voltage set to 1.6 kV. Peptides were separated using a 45 min reversed phase gradient with Solvent A (0.1% formic acid in water) and Solvent B (90% acetonitrile/0.1% formic acid). The flow rate was set to 0.3 μL/min, and the gradient was as follows: 0–5 min 3% B, 5–25 min 3–40% B, 25–26 min 40–90% B, 26-31 min 90% B, 31–32 min 90–3% B, 32–45 min 3% B. Mass spectrometry data acquisition was carried out using a ddMS2 IT HCD top 10 method. The full MS scan range was 350–1800 m/z with a resolution of 35,000. Charge states 2+ to 7+ were included with a dynamic exclusion time of 10 s. HCD fragmentation was carried out using a fixed collision energy of 30% with an isolation window of 2.0 m/z, resolution of 17,500, AGC target of 1e5, and maximum IT of 50 ms. The raw mass spectrometry data have been deposited to the ProteomeXchange Consortium36 via the PRIDE partner repository with the data set identifier PXD044705. Mass Spectrometry Data Analysis Raw mass spectrometry data was processed using MaxQuant version 2.1.3.0 with the match-between-runs algorithm and label-free quantification. All other parameters in MaxQuant were kept under the default settings. A Homo sapiens database from Swiss Prot (downloaded August 2022) was modified to include the sequence of the anti-FLAG M2 antibody (GenBank). This customized FASTA file was used for protein identification. The protein groups were then imported into Perseus, and the rows were filtered by categorical column to remove proteins only identified by site, reverse sequences, and potential contaminants. The data was then log2 transformed, and each sample was normalized to the intensity of the anti-FLAG M2 antibody to account for potential loading differences across samples, and then median-normalized. Replicates were filtered individually across samples, and each catalytically inactive mutant (CD1, CD2, CD1/2) was analyzed individually against its paired wild-type HDAC6 sample. Proteins that were of higher abundance in the vehicle control than the wild-type and mutant samples were removed to eliminate identifications from nonspecific binding. Proteins that had a higher abundance in the samples treated with Vorinostat were removed to eliminate potential interactors not present at the catalytic site. Proteins that were quantified in the mutant sample but not in the wild-type sample were considered significant. Varying levels of filtering stringency were applied, similar to the method employed by Nalawansha et al.30 The base filtering (Level 1) required proteins quantified in 2 of the 4 replicates to have log2(fold change (FC)) > 0.56 and then to increase the stringency filtering (Level 2) required proteins quantified in 3 of the 4 replicates to have log2(FC) > 0.56, and a higher stringency (Level 3) required proteins to be quantified in 3 of the 4 replicates to have log2(FC) > 1. Lastly, Level 4 required proteins to be quantified across all 4 replicates and a log2(FC) > 1 (Table S1). Gene Ontology Analysis GeneMania in Cytoscape was used to generate protein-interaction networks. Networks were restricted to evidence of physical interactions only, and network weighting was set to equal (by network).37 Cytoscape was also used to carry out pathway analysis. Description detail was automatically set by Cytoscape, and pathways were restricted to experimental evidence only and significant with a p-value of <0.05. Pie charts were created using GraphPad Prism. The DAVID functional annotation tool38,39 was used for additional pathway analysis presented in the bubble plots. Bubble plots were created using SRplot, a free online platform for data analysis and visualization.40 Results and Discussion Substrate Trapping Overview In this study, we utilized the method of substrate trapping to identify catalytic domain-specific substrates of HDAC6 in the context of HGSOC. Substrate trapping is an effective method that enables the characterization of transiently bound substrates of an enzyme of interest. This method is carried out by transfecting a catalytically inactive mutant of an enzyme into cells. The inactive enzyme then binds its substrates for an extended period of time, allowing for immunoprecipitation of the enzyme with its bound substrates. This is then followed by protein digestion and mass spectrometry analysis, which enables robust identification and quantification of potential substrates. We used three catalytically inactive HDAC6 mutants in this study: one containing a point mutation in catalytic domain 1 (CD1) (H216A), the second containing a point mutation in CD2 (H611A), and the third containing a dual point mutation in CD1 & CD2 (H216A/H611A) (Figure 1A). These point mutations have been used in previous studies of HDAC6 catalytic activity.31,42 When filtering the data, we used four levels of stringency (Table S1, Figure 1B). The base level of stringency (L1) required 2 of the 4 replicates to have a log2(FC) > 0.56. This level of filtering was used for pathway and network analyses. Significant Proteins Identified Across Mutant HDAC6 Conditions. (A) Substrate trapping conceptual figure. Created in BioRender. (B) Filtering scheme for significant proteins with four levels of stringency (L1-L4) and the corresponding number of proteins identified at each level for each mutant condition. (C) Protein overlap across each mutant condition from L1 of filtering. (D) Proteins shared between CD1 and CD2 conditions. Highlighted proteins are involved in DNA Damage Repair (DDR). HDAC6 Catalytic Domain Mutants Identify Known and Unique HDAC6 Substrates Structurally, the CD1 and CD2 active sites contain 356 amino acids each26 and are highly conserved with a narrow hydrophobic channel and Zn2+ coordination.41 However, there are slight differences in the amino acids forming the acetyl-lysine binding channel. For example, the bulkier Tryptophan (Trp261) in CD1 versus Phenylalanine (Phe643) in CD2,41 may be contributing to differing substrate specificities. Nonetheless, the structure–function relationships of the different catalytic domains have yet to be fully resolved. After our first level (L1) of protein filtering, there were 256 significant proteins identified under the CD1 condition (Table S2). These significant identifications included previously identified substrates of HDAC6 such as EIF4B, CTTN, and CTNNB1.31,42−45 EIF4B was significant at the highest level of stringency (L4) across all four replicates. We also identified PRTM5, which is in agreement with the results reported by Gomes et al.(31) (Table S2). However, in our data set, PRMT5 was only identified as a significant HDAC6-interacting protein in the CD1 mutant condition. The CD2 mutant pull-down identified 149 significant proteins (L1) (Table S3). Among the significant proteins was the previously known HDAC6 substrate tubulin (TUBG1, TUBB6, TUBB3, and TUBA1C) (Table S3). Tubulin was only identified as significant in the CD2 mutant pull-down, which aligns with previous studies.46−49 The CD1/2 double mutant condition resulted in the identification of 82 significant proteins (L1) (Figure 1B, Table S4). Of the 256 significant proteins in the CD1 condition, 32 overlapped with the CD2 condition (Figure 1C). Of these 32 genes, many have been identified as having varying roles in ovarian cancer progression and prognosis. Elevated abundances of AHNAK, ANXA1, and LAMA3 have been correlated with suppressed ovarian cancer growth and improved survival.50−52 CHD4, PFKFB3, and RSF1 have been associated with the regulation of drug response.53−55 The expression of FLI-1, KCD5, and PRSS3 has been associated with poor survival, and these proteins are potential prognostic markers.56−58 TP53 is also strongly linked to HGSOC as it is mutated in most HGSOC patients, leading to a gain or loss of function.59 Other DNA damage repair factors were also identified as significant across the CD1 and CD2 conditions: PRDKC, PARP9, and XRCC6 (Figure 1D, Table S5). Only three proteins were identified across all mutant conditions: MYO5B, OGT, and RIOK1 (Table S5). HDAC6 Primary Neighbor Interacting Proteins Differ Based on Catalytic Domain Activity Next, we carried out a network analysis to compare previously identified substrates of HDAC6 to those identified in our current data set. The data shown are restricted to first neighbors that have literature-based evidence of direct interactions with HDAC6. The DNA damage repair factor XRCC5 was identified as a first neighbor in the CD1 condition, and XRCC6 was identified as a first neighbor in both the CD1 and CD2 conditions (Figure 2A,B). In the CD2 condition, there is evidence of a higher confidence interaction between HDAC6 and PLAA, which has been previously associated with the suppression of ovarian cancer metastasis.60 In addition to XRCC6, GEMIN5 and PFKL were shared first neighbors under the CD1 and CD2 mutant conditions. ACTG1 was the only first neighbor that was shared between CD1 and CD1/2 (Figure 2A,C). Network Analysis of Protein Interactors with HDAC6. Network analysis was carried out using Genemania in Cytoscape. Network results were restricted to input proteins and physical interactions only and had an equal weighting (by network); all other settings were left as default. The resulting network was restricted to first-neighbors only. (A) CD1 (B) CD2 (C) CD1/2. Yellow highlighted genes are shared between CD1 and CD2. Green highlighted genes are shared between CD1 and CD1/2. DNA Damage Repair Pathways Were Identified as Significant in the CD1 and CD2 Conditions The most prevalent pathways identified under the CD1 condition included processes related to transcription, translation, and protein modification regulation (Figure 3A). Whereas translation and pyruvate metabolism comprised the majority of CD2 pathways (Figure 3B), the only pathway that overlapped between CD1 and CD2 was tRNA aminoacylation for protein translation. The CD1/2 condition consisted mostly of RNA metabolic process regulation and had no overlap with the CD1 or CD2 conditions (Figure 3C). These results from the CD1 condition strengthen the argument that this domain contains deacetylase activity that is independent of CD2. Pathway Analysis of Significant Proteins Identified Across HDAC6 Mutant Conditions. Pathway analysis was carried out using Cytoscape and restricted to experimental evidence only with a p-value of <0.05. All other settings were left as default. (A) CD1 (B) CD2 (C) CD1/2. Bolded text indicates pathways shared across CD1 and CD2 conditions. The CD1/2 dual mutant studied in this data set contained overall fewer identified interacting proteins than did the CD1 and CD2 plasmids. Only a small number of proteins (n = 16 and 5, respectively) were shared with either of the other two conditions. This was reflected by the pathway analysis differing greatly from the other two conditions. The presence of a point mutation in both catalytic domains may have impacted the functionality of HDAC6 and its ability to interact with substrates. The results from this double mutant could also suggest that both domains are required for deacetylase activity. DNA damage repair pathways were identified as being significant across the CD1 and CD2 conditions. Positive regulation of double-strand break repair via nonhomologous end joining was unique to the CD1 condition (Figure 4A). Double-strand break repair via alternative nonhomologous end joining and break-induced replication were unique to the CD2 condition (Figure 4B). DNA damage repair pathways were not among the significant pathways under the CD1/2 mutant condition. The CD1 and CD2 pulldowns each resulted in nine significant proteins involved in the DNA damage repair pathways. Four of those proteins were shared between the two conditions (TP53, PARP9, XRCC6, PRDKC) (Figures 4C,1D). The CD1 condition also yielded more transcriptional and translational pathways, which could be related to the large number of proteins identified under this condition (n = 256) compared to the CD2 and CD1/2 conditions (n = 149 and 82, respectively) (Figure 4C). These DNA damage repair factors contribute to the nonhomologous end joining DNA damage repair pathway. Gene Ontology Analysis of Individual Pathways Pertaining to DNA Damage Repair, Transcription and Translation. GO Enrichment Bubble Plot was plotted by SRplot. Pathway input was obtained from DAVID and limited to p-value <0.05. (A) CD1 Biological Processes. (B) CD2 Biological Processes. The size of the dot corresponds to the number of genes associated with that pathway. The color of the dot corresponds to the p-value significance of each pathway. (C) Overlap of proteins identified in each pathway across the HDAC6 mutant conditions. HDAC6 Interaction with Post-Translational Modification (PTM) Regulators Suggests the Occurrence of Acetylation, Phosphorylation, Methylation, and Ubiquitination Crosstalk All three mutant conditions contained post-translational modification (PTM) regulators as significant substrates, with the CD1 condition having the largest number of significant interactors (Figure 5A). All three conditions identified the protein kinases as HDAC6 interactors. RIOK1 was the only protein kinase identified across all three mutant conditions. RIOK1 was also identified with higher levels of stringency across the mutant conditions, which includes L4 in CD1, L3 in CD1/2, and L1 for CD2. PTM Regulators Identified as Significant Interactors across HDAC6 Mutant Conditions. (A) Number of significant PTM regulators across plasmid conditions. (B–D) Table of proteins identified in each condition: (B) CD1 (C) CD2 (D) CD1/2. Green highlighted boxes indicate methyltransferases. Red highlighted boxes indicate E3 Ubiquitin Ligases. Blue highlighted boxes indicate Kinases. The CD1 condition contained 20 kinases, 2 methyltransferases, and 8 E3 ubiquitin ligases (Figure 5B). There were no ubiquitin ligases identified under the CD2 condition (Figure 5C). However, the two methyltransferases identified in the CD2 condition were unique to the CD2 condition (DNMT1 and METTL13). DNMT1 was also identified in the higher level of stringency (L3). DTX3L, an E3 ubiquitin ligase that is involved in DNA damage repair, was also identified under CD1/2 conditions (Figure 5D). However, the CD1/2 condition had the least number of PTM regulators identified. Previous studies have shown that CD1 exhibits E3 ubiquitin ligase activity with certain substrates.31,61 In our data set, E3 ubiquitin ligase identifications were unique to the CD1 domain. E3 ubiquitin ligase can regulate cell trafficking and DNA repair. However, the CD1 and CD2 mutants resulted in the identification of methyltransferases and kinases as HDAC6-interacting proteins. The interaction of HDAC6 with multiple PTM regulators could be beneficial in determining the downstream impacts of inhibiting HDAC activity. The abundant HDAC6-kinase interactions could support a functional justification for the development of HDACi and kinase inhibitor combination therapies. This information could also be utilized to guide the development of alternative therapeutic opportunities for HGSOC. Conclusions In this study, we carried out substrate trapping to analyze HDAC6 interactors in the context of HGSOC. To consider HDACs as therapeutic targets, there is a need for an enhanced understanding of their function in HGSOC, including identifying their interacting proteins. The identification of HDAC targets will enable us to define their biological roles with functional consequences related to disease aggressiveness and drug sensitivity in HGSOC. The identification of HDAC substrates can lead to the development of more targeted therapeutics to minimize off-target effects from HDACi. We hypothesized that HDAC6 interacts with proteins involved in DNA damage repair and transcription to promote tumor progression and drug resistance. This analysis was carried out using three different catalytically dead HDAC6 mutants to determine the catalytic domain-specific HDAC6 interactors. Our identification of HDAC6 interactions with multiple PARP proteins further justifies the utility of HDAC inhibitors in combination with PARP inhibitors. However, the best combination of which PARP inhibitor and HDAC inhibitor to utilize together has yet to be determined. Two clinical trials evaluated the utility of HDAC inhibitors in combination with PARP inhibitors. Phase I clinical trial NCT03924245 assessed the utility of HDACi Entinostat with PARPi Olaparib in platinum-resistant ovarian cancers. The study was terminated in 2022 due to a lack of results and publication. A Phase I clinical trial assessing PARPi Talazoparib and HDACi Belinostat in metastatic ovarian cancer is currently recruiting participants (NCT04703920). One limitation of our study is the endogenous HDAC6 expression within the OVCAR3 cells, given that a knockdown or knockout biochemical approach was not pursued. Future work could incorporate the use of HDAC6 knockout cells. Our next steps include additional validation of the HDAC6 substrates identified in this study, expansion of this method into additional HGSOC cell lines with differing genetic backgrounds, and different types of ovarian cancer cell lines (non-high-grade serous). Supplementary studies can also be carried out to distinguish the hierarchy of the identified interacting proteins and whether these proteins are direct interactors or the result of protein complex formation. Future studies could incorporate the investigation of the non-catalytic domains of HDAC6, such as the ubiquitin-binding domain, to assess additional HDAC6-interacting proteins that are independent of its catalytic activity. Overall, this study identified new HDAC6 substrates that may be unique to ovarian cancer models. Additional substrates were also implicated in DNA damage repair, which further justifies the use of HDACi as a combination treatment with platinum chemotherapy agents and/or targeted inhibitors, such as PARP inhibitors, in ovarian cancer. Further investigation of other previously unknown substrates could elucidate their roles in HGSOC and their potential therapeutic utility. The identification of HDAC6 substrates and the role of these interactions could lead to the development of inhibitors targeting specific proteins that may be unique to ovarian cancer, expand treatment options, and improve overall patient survival.